Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study
Open Access
- 2 November 2024
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 74 (1) , 1-11
Abstract
Immune checkpoint inhibitor (ICI) therapies effectively treat a broadening spectrum of cancer entities but induce various immune-related side effects (irAEs). Recent reports suggest a correlation between ICI-induced systemic inflammation and thromboembolic events as well as an increased effectiveness by coadministration of anticoagulants. With cancer patients having a higher risk of thrombotic events per se, it is crucial to dissect and characterize the mechanisms that cause pro-coagulative effects induced by systemic tumor therapies and their potential interplay with anti-tumor response. A total of 31 patients with advanced skin cancer treated with either ICIs (n = 24) or BRAF/MEK inhibitors (n = 7) were longitudinally assessed for blood and coagulation parameters before as well as 7, 20 and 40 days after initiation of systemic tumor therapy. Changes were analyzed and compared between both groups. In addition, the influence of coagulation parameters on progression-free, recurrence-free and overall survival was investigated. The ICI cohort presented significantly increased factor VIII activity after one week of therapy (p 0.0225); while, protein S activity was reduced during the whole observation period. Additionally, von Willebrand factor activity and tissue factor concentrations increased under immunotherapy. Similar changes occurred under BRAF/MEK inhibitor therapy (BRAF/MEKi). Increased baseline levels of von Willebrand factor antigen and factor VIII:C before the start of ICI therapy correlated with a significantly higher risk of recurrence for patients receiving adjuvant immunotherapy. The findings suggest the induction of a pro-coagulant state under ICI and BRAF/MEKi and a role of coagulation parameters in the efficacy of ICI therapies.Keywords
Funding Information
- German Federal Ministry of Education and Research (01ZX1905A)
- Universitätsklinikum Erlangen
This publication has 45 references indexed in Scilit:
- Hemostasis and tumor immunityResearch and Practice in Thrombosis and Haemostasis, 2022
- Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint InhibitorsCurrent Cardiology Reports, 2021
- Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registriesCancer Medicine, 2021
- Inflammatory markers in autoimmunity induced by checkpoint inhibitorsJournal of Cancer Research and Clinical Oncology, 2021
- C-reactive protein as an early marker of immune-related adverse eventsJournal of Cancer Research and Clinical Oncology, 2019
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical TrialsJAMA Oncology, 2019
- Trousseau's syndrome triggered by an immune checkpoint blockade in a non‐small cell lung cancer patientEuropean Journal of Immunology, 2018
- Systemic treatments for metastatic cutaneous melanomaCochrane Database of Systematic Reviews, 2018
- Risk Factors for Deep Vein Thrombosis and Pulmonary EmbolismArchives of internal medicine (1960), 2000
- Trends in the Incidence of Deep Vein Thrombosis and Pulmonary EmbolismArchives of internal medicine (1960), 1998